Armistice Capital’s Immunocore IMCR Stock Holding History

Armistice Capital’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.3M	Buy	1,428,000 +240,000	+20%	+$7.1M	0.55%	28
2026 Q1	$35.8M	Buy	1,188,000 +90,000	+8%	+$2.91M	0.64%	24
2025 Q4	$38.1M	Buy	1,098,000 +274,000	+33%	+$9.67M	0.45%	35
2025 Q3	$29.9M	Buy	824,000 +146,000	+22%	+$4.96M	0.44%	33
2025 Q2	$21.3M	Sell	678,000 -300,000	-31%	-$9.32M	0.37%	44
2025 Q1	$29M	Sell	978,000 -222,000	-19%	-$6.66M	0.43%	46
2024 Q4	$35.4M	Sell	1,200,000 -64,000	-5%	-$2.02M	0.48%	39
2024 Q3	$39.3M	Buy	1,264,000 +288,000	+30%	+$10.5M	0.63%	32
2024 Q2	$33.1M	Buy	976,000 +812,000	+495%	+$41.4M	0.42%	42
2024 Q1	$10.7M	Sell	164,000 -148,000	-47%	-$10.2M	0.14%	98
2023 Q4	$21.3M	Sell	312,000 -88,000	-22%	-$4.57M	0.29%	58
2023 Q3	$20.8M	Sell	400,000 -28,000	-7%	-$1.66M	0.32%	55
2023 Q2	$25.7M	Buy	428,000 +50,000	+13%	+$2.85M	0.37%	52
2023 Q1	$18.7M	Buy	378,000 +42,000	+13%	+$2.36M	0.27%	68
2022 Q4	$19.2M	Buy	336,000 +20,000	+6%	+$1.13M	0.33%	58
2022 Q3	$14.8M	Buy	316,000 +48,000	+18%	+$2.29M	0.26%	66
2022 Q2	$10M	Buy	268,000 +88,000	+49%	+$2.86M	0.17%	79
2022 Q1	$5.38M	Buy	+180,000	New	+$4.54M	0.1%	84

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Armistice Capital's IMCR Position: Q2 2026 in Review

Armistice Capital increased its Immunocore (IMCR) stake by 20% in Q2 2026, buying an estimated $7.1M and bringing the position to 1,428,000 shares worth $45.3M. The position accounts for 0.55% of the portfolio, ranked #28.

Armistice Capital first reported a position in IMCR in Q1 2022 and has held it in 18 quarters since. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

Armistice Capital held 1,428,000 shares of Immunocore worth $45.3M as of Q2 2026.
Armistice Capital bought 240,000 Immunocore shares in Q2 2026, an estimated $7.1M.
Immunocore made up 0.55% of Armistice Capital's portfolio in Q2 2026, its #28 holding.
Armistice Capital first reported a position in Immunocore in Q1 2022 and has held it in 18 quarters since.
136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.